{
    "clinical_study": {
        "@rank": "93933", 
        "arm_group": [
            {
                "arm_group_label": "Gucomannan", 
                "arm_group_type": "Experimental"
            }, 
            {
                "arm_group_label": "Placebo pill", 
                "arm_group_type": "Placebo Comparator"
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of this study is to determine if the herb, Glucomannan, is an effective\n      non-pharmacological appetite suppressant for overweight or Class I obese patients.  The\n      study design will not include any other lifestyle changes which enhance weight loss in order\n      to completely isolate the effects of Glucomannan as a non-pharmacological appetite\n      suppressant."
        }, 
        "brief_title": "The Effects of Glucomannan on Weight Loss", 
        "completion_date": {
            "#text": "July 2011", 
            "@type": "Actual"
        }, 
        "condition": "Obesity", 
        "condition_browse": {
            "mesh_term": "Obesity"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:Subjects will be recruited based upon the category of them wanting to\n        lose 50 pounds.\n\n        Subjects must be able to swallow the capsule whole with water.\n\n        Exclusion Criteria:\n\n          1. Self-reported use of prescription medication other than hormonal birth control (such\n             as medication for diabetes, hypertension hypothyroidism, heart disease, cancer, etc.)\n\n          2. Pregnancy\n\n          3. Age younger than 21 or older than 60 years of age.\n\n          4. Screening for hypertension during the first laboratory visit that reveals a systole\n             greater than 120 and a diastole greater than 90.\n\n          5. BMI calculations based upon height and weight measurements at the first laboratory\n             visit that reveal a BMI less than 25 or greater than 35.\n\n          6. Self-reported iron-deficiency anemia, osteoporosis, and hypoglycemia."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "60 Years", 
            "minimum_age": "21 Years"
        }, 
        "enrollment": {
            "#text": "43", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "October 16, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01709955", 
            "org_study_id": "10-13"
        }, 
        "intervention": [
            {
                "arm_group_label": "Gucomannan", 
                "description": "750 MG of Glucomannan in capsule form", 
                "intervention_name": "Glucomannan", 
                "intervention_type": "Dietary Supplement"
            }, 
            {
                "arm_group_label": "Placebo pill", 
                "description": "750 mg of Cellulose powder in a capsule form", 
                "intervention_name": "Placebo", 
                "intervention_type": "Other"
            }
        ], 
        "intervention_browse": {
            "mesh_term": "(1-6)-alpha-glucomannan"
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "Obesity", 
            "Overweight", 
            "Glucomannan"
        ], 
        "lastchanged_date": "October 17, 2012", 
        "number_of_arms": "2", 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "United States: Institutional Review Board", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "July 2011", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "measure": "Weight Loss", 
            "safety_issue": "No", 
            "time_frame": "30 Days"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01709955"
        }, 
        "responsible_party": {
            "investigator_affiliation": "New York Chiropractic College", 
            "investigator_full_name": "Denise Holtzman MS DC", 
            "investigator_title": "Associate professor", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "source": "New York Chiropractic College", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "New York Chiropractic College", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "February 2011", 
        "study_design": "Allocation: Randomized, Intervention Model: Factorial Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "October 2012"
    }
}